Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ALKS 2680 in adults with narcolepsy type 1
NL-OMON61386Phase 3Not yet recruiting
- Sponsor
- Alkermes
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of alixorexton in narcolepsy type 1 (NT1), sponsored by Alkermes. Primary endpoint: Change in Epworth Sleepiness Scale. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
alixorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NL-OMON61386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61386.